Explore more publications!

Wisconsin Health Press: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wisconsin Health Press.

Press releases published on January 21, 2026

Flexagon extends DevOps platform for enterprise application configuration management
University of Virginia Announces First-in-Human Trial of Therapy for Sepsis-Induced Acute Respiratory Distress Syndrome
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth
Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgique Afin De Soutenir Sa Croissance Mondiale
Option Care Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
GRI Bio Announces Reverse Stock Split
Jushi Holdings Inc. Announces Grand Opening of Second Beyond Hello™ in Cincinnati, Ohio, Expanding its Statewide Retail Footprint
Premier Utah Medical Practice Announces New Collaboration with Nationally Recognized Cosmetic Dentist
Bay Alarm Medical named best Medical Alert System for 2026
Pharmacist and Pharmacy Organizations Including NASP Commend 2026 Spending Bill with Important PBM Provisions, Urge Passage
UPDATE - BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency
Jin Medical International Ltd. Management Plans For Fireside Chat
Maximizing Healthspan: HealthyLifetime Disrupts Cycle of Aging Decline and Launches as Independent Company
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions